Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBIT Margin (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of EBIT Margin data on record, last reported at 369.44% in Q3 2025.

  • For Q3 2025, EBIT Margin fell 1165.0% year-over-year to 369.44%; the TTM value through Sep 2025 reached 593.6%, down 51950.0%, while the annual FY2024 figure was 66.06%, N/A changed from the prior year.
  • EBIT Margin reached 369.44% in Q3 2025 per GOSS's latest filing, down from 337.41% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1612.12% in Q3 2022 and bottomed at 372.23% in Q1 2025.
  • Average EBIT Margin over 4 years is 664.91%, with a median of 843.91% recorded in 2023.
  • Peak YoY movement for EBIT Margin: tumbled -156898bps in 2024, then crashed -1165bps in 2025.
  • A 4-year view of EBIT Margin shows it stood at 1572.37% in 2022, then fell by -23bps to 1211.19% in 2023, then plummeted by -61bps to 476.62% in 2024, then crashed by -178bps to 369.44% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 369.44% in Q3 2025, 337.41% in Q2 2025, and 372.23% in Q1 2025.